Vitrolife interim report january - march 2004

Vitrolife interim report january - march 2004 ·Core business net sales increased by 14 per cent and amounted to SEK 29,5 million (25,9), corrected for currency effects the increase amounted to 18 per cent. ·The group´s gross margin improved to 69 per cent (62). ·Operating result improved and amounted to SEK 5,2 million (-2,2). ·Net result improved and amounted to SEK 6,0 million (-0,6). Result per share SEK 0,32 (-0,03). ·During the first quarter Vitrolife took over the sales in USA and Canada from distributors. CEO: Dr. Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 mnilsson@vitrolife.com Acting CFO and IR agent: Anders Sävfält Tel: +46 31 721 80 00 asavfalt@vitrolife.com Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas. · Europe/Middle East · The Americas · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/04/23/20041110BIT21690/wkr0001.pdf The full report in Swedish